Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: Hurdles might be ahead

British Journal of Cancer

Volumn 107, Issue 2, 2012, Pages 308-314

  Mangoni, M ^a,b,c   Vozenin, M C ^a,b   Biti, G ^c   Deutsch, E ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

anti VEGF antibody; radiation; toxicity

Indexed keywords

BEVACIZUMAB; BLEOMYCIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; EVALUATION; FEMALE; INTESTINE ULCER; LUNG FIBROSIS; MOUSE; NONHUMAN; ORAL MUCOSITIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; TOXICITY TESTING; WHOLE BODY RADIATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BLEOMYCIN; COMBINED MODALITY THERAPY; FEMALE; FIBROSIS; INTESTINES; LUNG; MICE; MICE, INBRED C57BL; MOUTH MUCOSA; RADIATION INJURIES, EXPERIMENTAL; RADIOTHERAPY; RADIOTHERAPY DOSAGE; STOMATITIS;

EID: 84863721152     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.236     Document Type: Article

References (37)

1. Carden CP, Larkin JM, Rosenthal MA (2008) What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 10: 624-630
2. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
3. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK (2011) Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 114: 1609-1616
4. Cornacoff JB, Howk K, Pikounis B, Mendenhall V, Martin P (2008) Development of a method for the evaluation of wound tensile strength in cynomolgus macaques. J Pharmacol Toxicol Methods 57: 74-79
5. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA (2006) Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24: 1145-1151
6. Deshaies I, Malka D, Soria JC, Massard C, Bahleda R, Elias D (2010) Antiangiogenic agents and late anastomotic complications. J Surg Oncol 101: 180-183
7. Deutsch E, Soria JC, Armand JP (2005) New concepts for phase I trials: evaluating new drugs combined with radiation therapy. Nat Clin Pract Oncol 2: 456-465
8. Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, Solomon SB (2011) Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 117: 1296-1301
9. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680
10. Gonzalez J, Kumar AJ, Conrad CA, Levin VA (2007) Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67: 323-326
11. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75: 156-163
12. Haston CK, Travis EL (1997) Murine susceptibility to radiation-induced pulmonary fibrosis is influenced by a genetic factor implicated in susceptibility to bleomycin-induced pulmonary fibrosis. Cancer Res 57: 5286-5291
13. Hendriks JM, Hubens G, Wuyts FL, Vermeulen P, Hubens A, Eyskens E (1999) Experimental study of intraperitoneal suramin on the healing of colonic anastomoses. Br J Surg 86: 1171-1175
14. Howdieshell TR, Callaway D, Webb WL, Gaines MD, Procter Jr CD, Sathyanarayana, Pollock JS, Brock TL, McNeil PL (2001) Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 96: 173-182
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
16. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62
17. Jeyaretna DS, Curry Jr WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR (2011) Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol 29: e159-e162
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65
19. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697-3705
20. Koukourakis MI (2001) Tumour angiogenesis and response to radiotherapy. Anticancer Res 21: 4285-4300
21. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29: 142-148
22. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF (2011) Randomized doubleblind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79: 1487-1495
23. Lind JSW, Senan S, Smit EF (2012) Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperabile stage III non-small-cell lung cancer. J Clin Oncol 30: e104-e108
24. Llena JF, Cespedes G, Hirano A, Zimmerman HM, Feiring EH, Fine D (1976) Vascular alterations in delayed radiation necrosis of the brain. An electron microscopical study. Arch Pathol Lab Med 100: 531-534
25. Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64: 1295-1298
26. Monceau V, Pasinetti N, Schupp C, Pouzoulet F, Opolon P, Vozenin MC (2010) Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity. Curr Drug Targets 11(11): 1395-1404
27. Parkins CS, Fowler JF, Yu S (1983) A murine model of lip epidermal/mucosal reactions to X-irradiation. Radiother Oncol 1: 159-165
28. Pietzner K, Richter R, Chekerov R, Erol E, Oskay-Ozcelik G, Lichtenegger W, Sehouli J (2011) Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group. Anticancer Res 31: 2679-2682
29. Scalliet P, Goor C, Galdermans D, Van Meerbeck J, Groen H, Van de Leest A (1998) Gemzars (gemcitabine) with thoracic radiotherapy-a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17: 499a
30. Schiffele F, Fuss IJ (2002) Induction of TNBS colitis in mice. Curr Protoc Immunol 15: 15-19
31. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE (2008) Phase I study of bevacizumab added to fluorouracil-and hydroxyureabased concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 26: 1732-1741
32. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, Farley C, Burris 3rd HA, Greco FA (2010) Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 28: 43-48
33. te Velde EA, Voest EE, van Gorp JM, Verheem A, Hagendoorn J, Gebbink MF, Borel Rinkes IH (2002) Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. Ann Surg Oncol 9: 303-309
34. Van Buren II G, Yang AD, Dallas NA, Gray MJ, Lim SJ, Xia L, Fan F, Somcio R, Wu Y, Hicklin DJ, Ellis LM (2008) Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 26: 1836-1842
35. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23: 8136-8139
36. Withers HR, Elkind MM (1970) Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat Stud Phys Chem Med 17: 261-267
37. Wong ET, Huberman M, Lu XQ, Mahadevan A (2008) Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 26: 5649-5650